Stockscreener 앱 받기
1.67
13.61%
0.20
시간 외 거래:
1.62
-0.05
-2.99%
전일 마감가:
$1.47
열려 있는:
$1.43
하루 거래량:
1.99M
Relative Volume:
0.97
시가총액:
$151.75M
수익:
$70.39M
순이익/손실:
$-43.97M
주가수익비율:
-3.2233
EPS:
-0.5181
순현금흐름:
$-23.85M
1주 성능:
-2.34%
1개월 성능:
+41.53%
6개월 성능:
-31.84%
1년 성능:
-37.22%
1일 변동 폭
$1.42
$1.67
1주일 범위
$1.41
$1.94
52주 변동 폭
$0.9583
$3.87
Codexis Inc Stock (CDXS) Company Profile
명칭
Codexis Inc
전화
650-421-8100
주소
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.67 | 133.58M | 70.39M | -43.97M | -23.85M | -0.5181 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-29 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-07 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-08-07 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2021-04-12 | 개시 | Piper Sandler | Overweight |
| 2021-03-01 | 개시 | Stifel | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-10 | 개시 | The Benchmark Company | Buy |
| 2019-01-17 | 업그레이드 | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | 개시 | Stephens | Overweight |
| 2017-10-13 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-31 | 개시 | Jefferies | Buy |
| 2017-01-26 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | 개시 | H.C. Wainwright | Buy |
모두보기
Codexis Inc 주식(CDXS)의 최신 뉴스
Codexis rises after Q4 beat, strong outlook - MSN
Why did Codexis (CDXS) stock soar nearly 38% after hours? - MSN
Biocatalysis and Biocatalysts Market is expected to Hit US$ 6.7 - openPR.com
Codexis (CDXS) beats Q4 earnings and revenue estimates - MSN
Codexis (CDXS) Is Up 30.9% After Merck-Fueled Q4 Profit Beat And 2026 Revenue GuidanceHas The Bull Case Changed? - simplywall.st
Short Interest in Codexis, Inc. (NASDAQ:CDXS) Grows By 26.2% - MarketBeat
Codexis (CDXS) Is Up 30.9% After Returning To Q4 Profitability And Issuing 2026 Revenue Guidance - Yahoo Finance
Codexis Faces Strategic Challenges Amidst Revenue Dip - timothysykes.com
Assessing Codexis (CDXS) Valuation After Strong Earnings And New ECO Synthesis siRNA Agreement - simplywall.st
Codexis (NASDAQ:CDXS) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - AOL.com
Codexis Stock Plummets Amid Financial Struggles - StocksToTrade
Why did CDXS stock jump 7% today? - MSN
Cantor Fitzgerald Maintains Overweight on Codexis (CDXS) March 2026 - Meyka
Codexis (CDXS) Q4 Profit Turns Positive EPS Into Test Of Turnaround Narrative - Sahm
Dow Tumbles Over 1%; US Weekly Jobless Claims Fall - Sahm
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours? - Sahm
Codexis (CDXS) Stock Jumps 2.4% Following Strong Q4 Earnings Report - MEXC
Stifel reiterates Codexis stock Buy rating on solid 2026 guidance - Investing.com UK
Cantor Fitzgerald reiterates Codexis stock rating on siRNA deal - Investing.com South Africa
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform (NASDAQ:CDXS) - Seeking Alpha
Codexis (CDXS) Stock Rises 2.4% After Q4 Earnings Beat - MEXC
Cantor Fitzgerald reiterates Codexis stock rating on siRNA deal By Investing.com - Investing.com India
Stifel reiterates Codexis stock Buy rating on solid 2026 guidance By Investing.com - Investing.com India
Crude Oil Surges Over 8%; Dollar General Shares Fall After Q4 Results - Benzinga
Codexis Shines as Q4 Profit Sparks Investor Enthusiasm - StocksToTrade
Codexis Surpasses Q4 Expectations, Stock Price Volatility Anticipated - timothysykes.com
Codexis (CDXS) Q4 2025 Earnings Call Transcript - AOL.com
Codexis stock jumps on Q4 earnings beat, strong 2026 outlook - National Today
Codexis (CDXS) Surges on Strong Q4 2025 Results and Optimistic O - GuruFocus
Codexis, Inc. (NASDAQ:CDXS) Q4 2025 Earnings Call Transcript - Insider Monkey
Codexis stock rises after Q4 beat, outlook (CDXS:NASDAQ) - Seeking Alpha
Codexis, Inc. 2025 Annual Report: Advancements in ECO Synthesis Platform and Pharma Biocatalysis for Therapeutics Manufacturing - Minichart
Codexis: Q4 Earnings Snapshot - theheraldreview.com
Codexis (CDXS) Expects Current Funds to Last Through 2027 - GuruFocus
Codexis Inc (CDXS) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... By GuruFocus - Investing.com Canada
Codexis Inc (CDXS) Q4 2025 Earnings Call Highlights: Revenue Sur - GuruFocus
Codexis, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Codexis Surpasses Q4 2025 Expectations with Strong Revenue Growth - Investing.com Nigeria
Codexis (CDXS) Surpasses Q4 Expectations for Earnings and Revenue - Bitget
CDXS: Strong 2025 revenue and ECO Synthesis progress set the stage for continued growth in 2026 - TradingView
Codexis Q4 Earnings Call Highlights - MarketBeat
Codexis Inc (CDXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):